Estrogen Delivery Methods Compared: Patch vs. Cream vs. Pill vs. Vaginal

Short answer: pills, patches, gels, and vaginal products all deliver estrogen, but they are not interchangeable. Oral and transdermal routes are systemic treatments for whole-body symptoms, with a different observed clotting-risk profile; low-dose vaginal estrogen is a local treatment for genitourinary symptoms and is not expected to help hot flashes.

Pills, patches, gels, creams, and vaginal products all deliver estrogen — but they're not competing versions of one treatment. Route changes how the medication enters your body, what it's actually meant to treat, and its risk profile in some real, measurable ways. Here's how they actually compare.

The First Split: Systemic vs. Local

Systemic estrogen reaches the bloodstream and can treat whole-body symptoms like hot flashes and night sweats. Local, low-dose vaginal estrogen primarily treats genital and urinary symptoms of menopause — it isn't designed or expected to touch vasomotor symptoms at all.^[1]That distinction matters more than the specific product name, because "estrogen cream" can mean two clinically different things: a transdermal estradiol cream meant for systemic treatment, or a low-dose vaginal cream meant for local treatment. It's the route, dose, and labeling that determines which one you're actually using — not the word "cream" itself.^[3]

Oral Estrogen: How It Works, and Why Route Matters for Clotting Risk

Oral estrogen is swallowed and absorbed through the digestive tract, passing through the liver before reaching general circulation. This "first-pass" liver effect can increase production of certain clotting-related factors, which is the mechanism behind oral therapy's different venous thromboembolism (VTE) risk profile compared to estrogen delivered through the skin.^[2] A large UK observational study found current oral HRT use was associated with increased VTE risk compared to no HRT use (adjusted odds ratio 1.58), while transdermal HRT showed no such association (odds ratio 0.93). Worth being precise here — this is an observational association, not proof the route alone caused the difference.^[4] The same study found the specific oral formulation matters too: estradiol-containing oral products carried lower VTE risk than conjugated-equine-estrogen products, though oral therapy overall still ran higher than no recent HRT use.^[4]

Transdermal (Patch, Gel, Spray): The Mechanism Advantage

A patch is a transdermal system — it releases estradiol through the skin directly into circulation, bypassing the liver's first-pass metabolism entirely. Gels and sprays work the same way, just without the adhesive patch format.^[2] The British Menopause Society states transdermal estradiol is unlikely to raise VTE or stroke risk above that of non-users, and carries lower risk than oral estradiol — their 2025 recommendations position transdermal as the first-choice route for anyone with relevant risk factors.^[5] ACOG frames it similarly: oral estrogen can have a prothrombotic effect, while transdermal estrogen has little to no effect on those same clotting substances. Route selection should still account for individual risk factors — obesity, immobility, recent fracture, or underlying clotting disorders.^[2]

Vaginal Estrogen: A Genuinely Different Category

Low-dose vaginal estrogen comes as creams, tablets/inserts, or rings, and is built for genitourinary syndrome of menopause (GSM) — vaginal dryness, burning or irritation, pain with sex, and some urinary symptoms.^[6]It's generally the right choice when genital or urinary symptoms are your main concern and there's no separate reason for systemic estrogen, like bothersome hot flashes. It's not expected to help vasomotor symptoms, since low-dose vaginal products don't provide meaningful systemic estrogen exposure.^[6]That's also why low-dose and ultra-low-dose vaginal estrogen doesn't require added progestogen for endometrial protection — the absorption is minimal enough that it doesn't raise endometrial hyperplasia risk the way systemic unopposed estrogen would.^[3]

A 2025 guideline from the American Urological Association, Society of Urodynamics, and American Urogynecologic Society — endorsed by the Menopause Society — recommends local low-dose vaginal estrogen for GSM-related dryness, discomfort, and pain with sex, and separately recommends it to reduce future recurrent UTIs in women with GSM and a history of them.^[6]Local vaginal estrogen can also be used alongside systemic therapy when GSM symptoms stick around even after systemic treatment improves hot flashes — a systemic regimen doesn't always fully resolve vaginal or urinary symptoms on its own.^[6]

Worth being honest about here too: vaginal estrogen isn't risk-free or universally appropriate regardless of history. Some outcomes still have limited long-term safety data, and women with a personal history of hormone-sensitive cancer should make this decision together with their treating clinician and, where relevant, their oncology team.^[6]

The Endometrial Protection Rule, Regardless of Route

If you have a uterus and use systemic estrogen — pill, patch, gel, or spray, doesn't matter which — you generally need a progestogen in an appropriate regimen to protect the endometrium. This applies to the systemic route as a category, not just to oral estrogen.^[1] Systemic estrogen without adequate progestogen protection can raise the risk of endometrial hyperplasia and endometrial cancer in women with a uterus.^[1]

At a Glance

The Bottom Line

These aren't interchangeable options — oral and transdermal estrogen are both systemic routes for whole-body symptoms, with a meaningfully different clotting-risk profile between them, while low-dose vaginal estrogen is a targeted, largely separate treatment for genitourinary symptoms. The right choice depends on your symptoms, uterus status, clotting and cardiovascular history, cancer history, and personal preference — a real clinical decision, not a matter of picking whichever format sounds most appealing.^[5]

Worth comparing which delivery methods different providers actually offer, since not every telehealth provider supports every route.

Frequently Asked Questions